BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 33052224)

  • 1. BET inhibitor suppresses melanoma progression
    Deng G; Zeng F; Su J; Zhao S; Hu R; Zhu W; Hu S; Chen X; Yin M
    Theranostics; 2020; 10(25):11428-11443. PubMed ID: 33052224
    [No Abstract]   [Full Text] [Related]  

  • 2. EEF2K silencing inhibits tumour progression through repressing SPP1 and synergises with BET inhibitors in melanoma.
    Deng G; Zeng F; He Y; Meng Y; Sun H; Su J; Zhao S; Cheng Y; Chen X; Yin M
    Clin Transl Med; 2022 Feb; 12(2):e722. PubMed ID: 35184394
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Tumor-Promoting Role of TRIP4 in Melanoma Progression and its Involvement in Response to BRAF-Targeted Therapy.
    Hao J; Xu H; Luo M; Yu W; Chen M; Liao Y; Zhang C; Zhao X; Jiang W; Hou S; Feng X; Zou K; Chen Y; Huang W; Guo W; Kang L; Deng W
    J Invest Dermatol; 2018 Jan; 138(1):159-170. PubMed ID: 28899685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
    Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
    Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Epigenetic Targeting of
    Huang M; Zeki J; Sumarsono N; Coles GL; Taylor JS; Danzer E; Bruzoni M; Hazard FK; Lacayo NJ; Sakamoto KM; Dunn JCY; Spunt SL; Chiu B
    Cancer Res; 2020 Mar; 80(5):1024-1035. PubMed ID: 31900258
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The interaction of YBX1 with G3BP1 promotes renal cell carcinoma cell metastasis via YBX1/G3BP1-SPP1- NF-κB signaling axis.
    Wang Y; Su J; Wang Y; Fu D; Ideozu JE; Geng H; Cui Q; Wang C; Chen R; Yu Y; Niu Y; Yue D
    J Exp Clin Cancer Res; 2019 Sep; 38(1):386. PubMed ID: 31481087
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nucleosome assembly protein 1-like 4, a new therapeutic target for proliferation and invasion of melanoma cells.
    Mizuhashi S; Fukushima S; Ishibashi T; Kuriyama H; Kimura T; Kanemaru H; Kajihara I; Makino K; Miyashita A; Aoi J; Kita K; Ihn H
    J Dermatol Sci; 2021 Apr; 102(1):16-24. PubMed ID: 33583643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. AZD5153: A Novel Bivalent BET Bromodomain Inhibitor Highly Active against Hematologic Malignancies.
    Rhyasen GW; Hattersley MM; Yao Y; Dulak A; Wang W; Petteruti P; Dale IL; Boiko S; Cheung T; Zhang J; Wen S; Castriotta L; Lawson D; Collins M; Bao L; Ahdesmaki MJ; Walker G; O'Connor G; Yeh TC; Rabow AA; Dry JR; Reimer C; Lyne P; Mills GB; Fawell SE; Waring MJ; Zinda M; Clark E; Chen H
    Mol Cancer Ther; 2016 Nov; 15(11):2563-2574. PubMed ID: 27573426
    [TBL] [Abstract][Full Text] [Related]  

  • 9. MicroRNA-22 targets FMNL2 to inhibit melanoma progression via the regulation of the Wnt/β-catenin signaling pathway and epithelial-mesenchymal transition.
    Shi L; Huo JW; Chen SS; Xue JX; Gao WY; Li XY; Song YH; Xu HT; Zhu XW; Chen K
    Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5332-5342. PubMed ID: 31298385
    [TBL] [Abstract][Full Text] [Related]  

  • 10. miR-140-5p is negatively correlated with proliferation, invasion, and tumorigenesis in malignant melanoma by targeting SOX4 via the Wnt/β-catenin and NF-κB cascades.
    Zhao G; Yin Y; Zhao B
    J Cell Physiol; 2020 Mar; 235(3):2161-2170. PubMed ID: 31385607
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Super-enhancers define a proliferative PGC-1α-expressing melanoma subgroup sensitive to BET inhibition.
    Gelato KA; Schöckel L; Klingbeil O; Rückert T; Lesche R; Toedling J; Kalfon E; Héroult M; Lejeune P; Mönning U; Fernández-Montalván AE; Bäurle S; Siegel S; Haendler B
    Oncogene; 2018 Jan; 37(4):512-521. PubMed ID: 28991225
    [TBL] [Abstract][Full Text] [Related]  

  • 12. microRNA-7-5p inhibits melanoma cell proliferation and metastasis by suppressing RelA/NF-κB.
    Giles KM; Brown RA; Ganda C; Podgorny MJ; Candy PA; Wintle LC; Richardson KL; Kalinowski FC; Stuart LM; Epis MR; Haass NK; Herlyn M; Leedman PJ
    Oncotarget; 2016 May; 7(22):31663-80. PubMed ID: 27203220
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Bromodomain protein BRD4 controls HOTAIR, a long noncoding RNA essential for glioblastoma proliferation.
    Pastori C; Kapranov P; Penas C; Peschansky V; Volmar CH; Sarkaria JN; Bregy A; Komotar R; St Laurent G; Ayad NG; Wahlestedt C
    Proc Natl Acad Sci U S A; 2015 Jul; 112(27):8326-31. PubMed ID: 26111795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Karyopherin α 2 promotes proliferation, migration and invasion through activating NF-κB/p65 signaling pathways in melanoma cells.
    Yang F; Li S; Cheng Y; Li J; Han X
    Life Sci; 2020 Jul; 252():117611. PubMed ID: 32243925
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overexpression of CDCA8 promotes the malignant progression of cutaneous melanoma and leads to poor prognosis.
    Ci C; Tang B; Lyu D; Liu W; Qiang D; Ji X; Qiu X; Chen L; Ding W
    Int J Mol Med; 2019 Jan; 43(1):404-412. PubMed ID: 30431060
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Combined Targeting of the BRD4-NUT-p300 Axis in NUT Midline Carcinoma by Dual Selective Bromodomain Inhibitor, NEO2734.
    Morrison-Smith CD; Knox TM; Filic I; Soroko KM; Eschle BK; Wilkens MK; Gokhale PC; Giles F; Griffin A; Brown B; Shapiro GI; Zucconi BE; Cole PA; Lemieux ME; French CA
    Mol Cancer Ther; 2020 Jul; 19(7):1406-1414. PubMed ID: 32371576
    [TBL] [Abstract][Full Text] [Related]  

  • 17. BET bromodomain inhibitors suppress EWS-FLI1-dependent transcription and the IGF1 autocrine mechanism in Ewing sarcoma.
    Loganathan SN; Tang N; Fleming JT; Ma Y; Guo Y; Borinstein SC; Chiang C; Wang J
    Oncotarget; 2016 Jul; 7(28):43504-43517. PubMed ID: 27259270
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of the BD2 bromodomain of BET proteins in prostate cancer.
    Faivre EJ; McDaniel KF; Albert DH; Mantena SR; Plotnik JP; Wilcox D; Zhang L; Bui MH; Sheppard GS; Wang L; Sehgal V; Lin X; Huang X; Lu X; Uziel T; Hessler P; Lam LT; Bellin RJ; Mehta G; Fidanze S; Pratt JK; Liu D; Hasvold LA; Sun C; Panchal SC; Nicolette JJ; Fossey SL; Park CH; Longenecker K; Bigelow L; Torrent M; Rosenberg SH; Kati WM; Shen Y
    Nature; 2020 Feb; 578(7794):306-310. PubMed ID: 31969702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Secreted Phosphoprotein 1 (SPP1) Contributes to Second-Generation EGFR Tyrosine Kinase Inhibitor Resistance in Non-Small Cell Lung Cancer.
    Wang X; Zhang F; Yang X; Xue M; Li X; Gao Y; Liu L
    Oncol Res; 2019 Aug; 27(8):871-877. PubMed ID: 30832751
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SPP1, analyzed by bioinformatics methods, promotes the metastasis in colorectal cancer by activating EMT pathway.
    Xu C; Sun L; Jiang C; Zhou H; Gu L; Liu Y; Xu Q
    Biomed Pharmacother; 2017 Jul; 91():1167-1177. PubMed ID: 28531945
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 25.